How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Nitric Oxide Therapy Instrument Market
- By Product Type: Portable Nitric Oxide Therapy Devices, Stationary Nitric Oxide Therapy Devices, Nitric Oxide Generators, Nitric Oxide Delivery Systems, Nitric Oxide Monitors
- By Application: Pulmonary Hypertension Treatment, Neonatal Respiratory Care, Wound Healing Therapy, Cardiovascular Disease Management, Erectile Dysfunction Therapy
- By End User: Hospitals, Clinics, Home Healthcare Settings, Research Laboratories, Rehabilitation Centers
- By Technology: Electrochemical Nitric Oxide Generation, Chemical Nitric Oxide Generation, Gas Cylinder-based Delivery, Integrated Monitoring Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Portable Nitric Oxide Therapy Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Nitric Oxide Therapy Instrument Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →INO Therapeutics LLC (a subsidiary of Mallinckrodt Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Vero Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pulmonox Medical Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bellerophon Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →SLE Enterprises
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Praxis Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Vyaire Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Linde plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Air Liquide Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nidek Medical Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Nox Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Beneq Oy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Nihon Kohden Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Masimo Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Fisher & Paykel Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Portable Nitric Oxide Therapy Devices51.6
- Stationary Nitric Oxide Therapy Devices7.1
- Nitric Oxide Generators15.8
- Nitric Oxide Delivery Systems14.7
- Nitric Oxide Monitors10.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- INO Therapeutics LLC (a subsidiary of Mallinckrodt Pharmaceuticals)19.6
- Vero Biotech15.7
- Pulmonox Medical Technologies12.8
- Bellerophon Therapeutics7.4
- SLE Enterprises10.2
- Praxis Biotech6.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe21.7
- Asia Pacific22.4
- Latin America12.4
- Middle East and Africa10.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| INO Therapeutics LLC (a subsidiary of Mallinckrodt Pharmaceuticals) | 90 | 74 | 79 | 99 | 84 | 94 | 87 |
| Vero Biotech | 70 | 85 | 74 | 78 | 92 | 81 | 80 |
| Pulmonox Medical Technologies | 87 | 82 | 65 | 66 | 86 | 70 | 76 |
| Bellerophon Therapeutics | 60 | 71 | 70 | 76 | 80 | 57 | 69 |
| SLE Enterprises | 75 | 67 | 51 | 68 | 73 | 66 | 67 |
| Praxis Biotech | 47 | 51 | 56 | 51 | 67 | 51 | 54 |
| Vyaire Medical | 41 | 52 | 53 | 64 | 48 | 48 | 51 |
| Linde plc | 58 | 49 | 59 | 58 | 56 | 43 | 54 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- INO Therapeutics LLC (a subsidiary of Mallinckrodt Pharmaceuticals)
- Vero Biotech
- Pulmonox Medical Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| INO Therapeutics LLC (a subsidiary of Mallinckrodt Pharmaceuticals) | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Vero Biotech | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Pulmonox Medical Technologies | ◐ | ✓ | − | ✓ | ✓ | ✓ |
| Bellerophon Therapeutics | − | ◐ | ✓ | ✓ | ◐ | ◐ |
| SLE Enterprises | ◐ | − | ◐ | − | ◐ | ◐ |
| Praxis Biotech | − | ◐ | − | − | ◐ | ◐ |
| Vyaire Medical | − | ◐ | − | ◐ | ◐ | ◐ |
| Linde plc | ◐ | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Product Type in North America, then scale across Nitric Oxide Therapy Instrument Market — a $133M beachhead inside a $1.78B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Portable Nitric Oxide Therapy Devices
Best fit — highest urgency & budget in Product Type.
Stationary Nitric Oxide Therapy Devices
Strong fit — clear ROI and a fast path to value.
Nitric Oxide Generators
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Nitric Oxide Therapy Instrument Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Nitric Oxide Therapy Instrument Market is a durable-growth opportunity — $4.17B by 2033, compounding at 7.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.6% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Nitric Oxide Therapy Instrument Market — a $1.94B market by 2033. Plan: grow share from 8.0% to 16.6%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 16.6% | On track |
| Revenue | $145M | $322M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.4% | 44.0% | At risk |
| Customer retention | 91.7% | 95.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Nitric Oxide Therapy Instrument Market conversation — a $4.91B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Nitric Oxide Therapy Instrument Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Nitric Oxide Therapy Instrument Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Nitride Ceramic Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportNitride Epitaxy Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportNitride LED Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportNitride Sputtering Target Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportNitrided Ferrochrome Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportNitrided Screw Market
Market size, share, segmentation and regional forecast.
$443M market · 2025 base year
View reportNitrides and Oxides based Hard Coatings Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportNitrile Amines Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportNitrile Butadiene Rubber (NBR) Sheets Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportNitrile Butadiene Rubber Latex Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportNitrile Butadiene Rubber Power Market
Market size, share, segmentation and regional forecast.
$859M market · 2025 base year
View reportNitrile Examination Glove Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy